# Different First-line Immunotherapy for Advancer Hepatocellular Carcinoma: A Prospective Observational Study on Efficacy and Immune Microenvironment

> **NCT07147101** · — · RECRUITING · sponsor: **Fudan University** · enrollment: 150 (estimated)

## Conditions studied

- Advanced Hepatocellular Carcinoma (HCC)

## Interventions

- **DRUG:** Sintilimab
- **DRUG:** Bevacizumab Biosimilar
- **DRUG:** Camrelizumab
- **DRUG:** Rivoceranib
- **DRUG:** Nivolumab
- **DRUG:** Ipilimumab

## Key facts

- **NCT ID:** NCT07147101
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-01
- **Primary completion:** 2028-09-01
- **Final completion:** 2028-09-01
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2026-04-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07147101

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07147101, "Different First-line Immunotherapy for Advancer Hepatocellular Carcinoma: A Prospective Observational Study on Efficacy and Immune Microenvironment". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT07147101. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*